Acute myeloid leukemia targets for bispecific antibodies

Mostrar otras versiones (1)

Despite substantial gains in our understanding of the genomics of acute myelogenous leukemia (AML), patient survival remains unsatisfactory especially among the older age group. T cell-based therapy of lymphoblastic leukemia is rapidly advancing; however, its application in AML is still lagging behi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoseini, S S, Cheung, N K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386336/
https://www.ncbi.nlm.nih.gov/pubmed/28157217
http://dx.doi.org/10.1038/bcj.2017.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5386336/
https://www.ncbi.nlm.nih.gov/pubmed/28157217
http://dx.doi.org/10.1038/bcj.2017.2

Ejemplares similares